Cholangiocarcinoma (CCA) is a liver malignancy associated with a poor prognosis. Its main subtypes are peripheral/intrahepatic and hilar/extrahepatic CCA. Several molecular, morphological and clinical similarities between hilar/extrahepatic CCA and pancreatic ductal adenocarcinoma (PDAC) have been described. FOXF1 is a transcription factor which has been described to have prognostic significance in various tumors and it is involved in the development of bile ducts. The aim of this study is to determine occurrence of nuclear expression of FOXF1 in both subtypes of CCA and metastatic PDAC and assess its potential usefulness as a diagnostic marker. Secondary aims were to investigate the use of C-reactive protein (CRP) immunohistochemistry for diagnosing intrahepatic peripheral CCA and the significance of histological features in CCA subtypes. 32 archive specimens of CCA, combined hepatocellular carcinoma-CCA (HCC-CCA) and liver metastasis of PDAC were stained by FOXF1 and CRP immunohistochemistry and evaluated to determine histological pattern. The CCAs were classified radiologically into peripheral/intrahepatic and hilar subtype. Using Fisher exact test, we identified nuclear FOXF1 as a fairly specific (87%) but insensitive (65%) marker of hilar and extrahepatic CCA and metastatic PDAC (p = 0.005). CRP immunohistochemistry was characterized by a high sensitivity and specificity, of 79% and 88%, respectively (p = 0.001). We did not identify any histomorphological features associated with either types of CCA or metastatic PDAC. As a conclusion of novel finding, FOXF1 immunohistochemistry may be regarded as a specific but insensitive marker of hilar/extrahepatic CCA and metastatic PDAC and it may help distinguish them from peripheral CCA.

Clinical and Transplant Pathology Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of General Surgery Charles University 3rd Faculty of Medicine Charles University University Hospital Královské Vinohrady Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University University Hospital Královské Vinohrady Prague Czech Republic

Department of Radiodiagnostics Charles University 3rd Faculty of Medicine Charles University and Královské Vinohrady University Hospital Prague Czech Republic

See more in PubMed

Nakanuma Y, Klimstra DS, Komuta M, Zen Y. Intrahepatic cholangiocarcinoma. In: WHO Classification of Tumors Editorial Board. Digestive system tumors, WHO classification of tumors series. 5th ed. Vol. 1. Lyon, France: International Agency for Research on Cancer; (2019), p. 254–9.

Roa JC, Adsay NV, Arola J, Tsui WM, Zen Y. Carcinoma of the gallbladder. In: WHO classification of tumors editorial board. Digestive system tumors, WHO classification of tumors series. Vol. 1. Lyon, France: International Agency for Research on Cancer. 5th ed. (2019), p. 283–8.

Roa JC, Adsay NV, Arola J, Tsui WM, Zen Y. Carcinoma of the extrahepatic bile ducts. In: WHO Classification of Tumors Editorial Board. Digestive system tumors, WHO classification of tumors series. 5th ed. Vol. 1. Lyon, France: International Agency for Research on Cancer; (2019), p. 289–91.

Sempoux C, Kakar S, Kondo F, Schirmacher P. Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In: WHO classification of tumors editorial board. Digestive system tumors. 5th ed. Vol. 1. Lyon, France: International Agency for Research on Cancer; (2019), p. 260–2.

Guedj N, Bedossa P, Paradis V. Anatomopathologie des cholangiocarcinomes. Ann de Pathologie (2010) 30(6):455–63. 10.1016/j.annpat.2010.10.004 PubMed DOI

Gandou C, Harada K, Sato Y, Igarashi S, Sasaki M, Ikeda H, et al. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Hum Pathol (2013) 44(5):811–21. 10.1016/j.humpath.2012.08.004 PubMed DOI

Nakanuma Y, Sato Y. Hilar cholangiocarcinoma is pathologically similar to pancreatic duct adenocarcinoma: suggestions of similar background and development. J Hepatob Pancreat Sci (2014) 21(7):441–7. 10.1002/jhbp.70 PubMed DOI

Lepreux S, Bioulac-Sage P, Chevet E. Differential expression of the anterior gradient protein-2 is a conserved feature during morphogenesis and carcinogenesis of the biliary tree. Liver Int (2011) 31(3):322–8. 10.1111/j.1478-3231.2010.02438.x PubMed DOI

Yeh Y-C, Lei H-J, Chen M-H, Ho H-L, Chiu L-Y, Li C-P, et al. C-reactive protein (CRP) is a promising diagnostic immunohistochemical marker for intrahepatic cholangiocarcinoma and is associated with better prognosis. Am J Surg Pathol (2017) 41(12):1630–41. 10.1097/PAS.0000000000000957 PubMed DOI

Shahid M, Mubeen A, Tse J, Kakar S, Bateman AC, Borger D, et al. Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation. Am J Surg Pathol (2015) 39(1):25–34. 10.1097/PAS.0000000000000343 PubMed DOI PMC

Cardinale V, Bragazzi MC, Carpino G, Torrice A, Fraveto A, Gentile R, et al. Cholangiocarcinoma: increasing burden of classifications. Hepatob Surg Nutr (2013) 2(5):272–80. 10.3978/j.issn.2304-3881.2013.10.02 PubMed DOI PMC

Tan JCC, Coburn NG, Baxter NN, Kiss A, Law CHL. Surgical management of intrahepatic cholangiocarcinoma - a population-based study. Ann Surg Oncol (2008) 15(2):600–8. 10.1245/s10434-007-9627-x PubMed DOI

Peterson RS, Lim L, Ye H, Zhou H, Overdier DG, Costa RH. The winged helix transcriptional activator HFH-8 is expressed in the mesoderm of the primitive streak stage of mouse embryos and its cellular derivatives. Mech Dev (1997) 69:53–69. 10.1016/s0925-4773(97)00153-6 PubMed DOI

Kalinichenko VV, Lim L, Stolz DB, Shin B, Rausa FM, Clark J, et al. Defects in pulmonary vasculature and perinatal lung hemorrhage in mice heterozygous null for the Forkhead Box f1 transcription factor. Dev Biol (2001) 235(2):489–506. 10.1006/dbio.2001.0322 PubMed DOI

Kalinichenko VV, Gusarova GA, Kim I-M, Shin B, Yoder HM, Clark J, et al. FOXF1 haploinsufficiency reduces Notch-2 signaling during mouse lung development. Am J Physiol Lung Cell Mol Physiol (2004) 286(3):L521–L530. 10.1152/ajplung.00212.2003 PubMed DOI

Szafranski P, Yang Y, Nelson MU, Bizzarro MJ, Morotti RA, Langston C, et al. Novel FOXF1 deep intronic deletion causes lethal lung developmental disorder, alveolar capillary dysplasia with misalignment of pulmonary veins. Hum Mutat (2013) 34(11):1467–71. 10.1002/humu.22395 PubMed DOI PMC

Szafranski P, Dharmadhikari AV, Wambach JA, Towe CT, White FV, Grady RM, et al. Two deletions overlapping a distant FOXF1 enhancer unravel the role of lncRNALINC01081in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins. Am J Med Genet (2014) 164(8):2013–9. 10.1002/ajmg.a.36606 PubMed DOI PMC

Szafranski P, Herrera C, Proe LA, Coffman B, Kearney DL, Popek E, et al. Narrowing the FOXF1 distant enhancer region on 16q24.1 critical for ACDMPV. Clin Epigenet (2016) 8:112. 10.1186/s13148-016-0278-2 PubMed DOI PMC

Szafranski P, Gambin T, Dharmadhikari AV, Akdemir KC, Jhangiani SN, Schuette J, et al. Pathogenetics of alveolar capillary dysplasia with misalignment of pulmonary veins. Hum Genet (2016) 135(5):569–86. 10.1007/s00439-016-1655-9 PubMed DOI PMC

Steiner LA, Getman M, Schiralli Lester GM, Iqbal MA, Katzman P, Szafranski P, et al. Disruption of normal patterns of FOXF1 expression in a lethal disorder of lung development. J Med Genet (2020) 57(5):296–300. 10.1136/jmedgenet-2019-106095 PubMed DOI

Kalinichenko VV, Zhou Y, Bhattacharyya D, Kim W, Shin B, Bambal K, et al. Haploinsufficiency of the mouse Forkhead Box f1 gene causes defects in gall bladder development. J Biol Chem (2002) 277(14):12369–74. 10.1074/jbc.M112162200 PubMed DOI

Lo P-K, Lee JS, Chen H, Reisman D, Berger FG, Sukumar S. Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas. Exp Mol Pathol (2013) 94(1):262–9. 10.1016/j.yexmp.2012.10.014 PubMed DOI PMC

Carpino G, Cardinale V, Onori P, Franchitto A, Berloco PB, Rossi M, et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat (2012) 220:186–99. 10.1111/j.1469-7580.2011.01462.x PubMed DOI PMC

Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenbergen W, Verslype C, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 55:1876–88. 10.1002/hep.25595 PubMed DOI

Spence JR, Lange AW, Lin S-CJ, Kaestner KH, Lowy AM, Kim I, et al. Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. Dev Cell (2009) 17:62–74. 10.1016/j.devcel.2009.05.012 PubMed DOI PMC

Fukuda A, Kawaguchi Y, Furuyama K, Kodama S, Horiguchi M, Kuhara T, et al. Ectopic pancreas formation in Hes1-knockout mice reveals plasticity of endodermal progenitors of the gut, bile duct, and pancreas. J Clin Invest (2006) 116(6):1484–93. 10.1172/JCI27704 PubMed DOI PMC

Wei H-J, Nickoloff JA, Chen W-H, Liu H-Y, Lo W-C, Chang Y-T, et al. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells. Oncotarget (2014) 5:9514–29. 10.18632/oncotarget.2413 PubMed DOI PMC

Malin D, Kim I-M, Boetticher E, Kalin TV, Ramakrishna S, Meliton L, et al. Forkhead box F1 is essential for migration of mesenchymal cells and directly induces integrin-beta3 expression. Mol Cell Biol (2007) 27:2486–98. 10.1128/MCB.01736-06 PubMed DOI PMC

Wang S, Yan S, Zhu S, Zhao Y, Yan J, Xiao Z, et al. FOXF1 induces epithelial-mesenchymal transition in colorectal cancer metastasis by transcriptionally activating SNAI1. Neoplasia (2018) 20(10):996–1007. 10.1016/j.neo.2018.08.004 PubMed DOI PMC

Wang S, Xiao Z, Hong Z, Jiao H, Zhu S, Zhao Y, et al. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA. Cancer Lett (2018) 439:78–90. 10.1016/j.canlet.2018.09.026 PubMed DOI

Saito R-A, Micke P, Paulsson J, Augsten M, Peña C, Jönsson P, et al. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res (2010) 70(7):2644–54. 10.1158/0008-5472.CAN-09-3644 PubMed DOI

Zhao ZG, Wang DQ, Hu DF, Li YS, Liu SH. Decreased FOXF1 promotes hepatocellular carcinoma tumorigenesis, invasion, and stemness and is associated with poor clinical outcome. Onco Targets Ther (2016) 9:1743–52. 10.2147/OTT.S95002 PubMed DOI PMC

Lo P-K, Lee JS, Liang X, Han L, Mori T, Fackler MJ, et al. Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res (2010) 70:6047–58. 10.1158/0008-5472.CAN-10-1576 PubMed DOI PMC

Nilsson J, Helou K, Kovács A, Bendahl P-O, Bjursell G, Fernö M, et al. Nuclear Janus-activated kinase 2/nuclear factor 1-C2 suppresses tumorigenesis and epithelial-to-mesenchymal transition by repressing Forkhead box F1. Cancer Res (2010) 70:2020–9. 10.1158/0008-5472.CAN-09-1677 PubMed DOI